The first U.S. surgical usage of Aurora Spine Corporation’s AmnioPUR took place this October in a lumbar spine procedure. AmnioPUR is a multipurpose, chorion free, cryopreserved allograft derived from the amniotic membrane. “The clinical benefit of amnion is well documented; we just made it easier to use by providing AmnioPUR in a liquid form, ” said Brent W. Johnston, CCO of Aurora Spine.
AmnioPUR Gets First U.S. Usage
1 min read Premium comments
Secondary
According to the firm’s news release, AmnioPUR provides an anti-microbial environment with anti-inflammatory characteristics and anti-adhesion/anti-fibrotic capabilities and provides a structural matrix for use in filling bone voids and soft tissue.
“The launch of AmnioPUR is a major milestone for Aurora Spine, as we now offer surgeons a comprehensive liquid allograft solution from a provider they trust, ” said Trent J. Northcutt, Aurora president and CEO. “Surgeons know Aurora provides modern technologies for today’s patients ailing from spinal complications.”
Aurora Spine describes itself as being an early stage company focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.